D
VYNE Therapeutics Inc.
VYNE
$1.56
$0.0755.07%
D
Sell
3/28/2025Upgraded
VYNE Therapeutics Inc. (VYNE) was upgraded to D- from E+ on 3/28/2025 due to an increase in the volatility index and valuation index.
VYNE Therapeutics Inc. (VYNE) was upgraded to D- from E+ on 3/28/2025 due to an increase in the volatility index and valuation index.
E
Sell
3/13/2025Downgrade
VYNE Therapeutics Inc. (VYNE) was downgraded to E+ from D- on 3/13/2025 due to a decline in the solvency index, volatility index and total return index. The quick ratio declined from 5.54 to 4.15.
VYNE Therapeutics Inc. (VYNE) was downgraded to E+ from D- on 3/13/2025 due to a decline in the solvency index, volatility index and total return index. The quick ratio declined from 5.54 to 4.15.
D
Sell
3/7/2025Upgraded
VYNE Therapeutics Inc. (VYNE) was upgraded to D- from E+ on 3/7/2025 due to an increase in the volatility index.
VYNE Therapeutics Inc. (VYNE) was upgraded to D- from E+ on 3/7/2025 due to an increase in the volatility index.
E
Sell
2/18/2025Downgrade
VYNE Therapeutics Inc. (VYNE) was downgraded to E+ from D- on 2/18/2025 due to a decline in the volatility index and total return index.
VYNE Therapeutics Inc. (VYNE) was downgraded to E+ from D- on 2/18/2025 due to a decline in the volatility index and total return index.
D
Sell
1/29/2025Upgraded
VYNE Therapeutics Inc. (VYNE) was upgraded to D- from E+ on 1/29/2025 due to an increase in the total return index, volatility index and valuation index.
VYNE Therapeutics Inc. (VYNE) was upgraded to D- from E+ on 1/29/2025 due to an increase in the total return index, volatility index and valuation index.
E
Sell
1/13/2025Downgrade
VYNE Therapeutics Inc. (VYNE) was downgraded to E+ from D- on 1/13/2025 due to a noticeable decline in the growth index, solvency index and valuation index. Total revenue declined 38.89% from $198 to $121, earnings per share declined from -$0.2209 to -$0.2855, and EBIT declined 25.92% from -$10.4M to -$13.09M.
VYNE Therapeutics Inc. (VYNE) was downgraded to E+ from D- on 1/13/2025 due to a noticeable decline in the growth index, solvency index and valuation index. Total revenue declined 38.89% from $198 to $121, earnings per share declined from -$0.2209 to -$0.2855, and EBIT declined 25.92% from -$10.4M to -$13.09M.
D
Sell
10/7/2024Upgraded
VYNE Therapeutics Inc. (VYNE) was upgraded to D- from E+ on 10/7/2024 due to an increase in the volatility index.
VYNE Therapeutics Inc. (VYNE) was upgraded to D- from E+ on 10/7/2024 due to an increase in the volatility index.
E
Sell
8/19/2024Downgrade
VYNE Therapeutics Inc. (VYNE) was downgraded to E+ from D- on 8/19/2024 due to a decline in the growth index, solvency index and total return index. Earnings per share declined from -$0.1502 to -$0.2209, the quick ratio declined from 12.4 to 6.64, and EBIT declined 40.87% from -$7.38M to -$10.4M.
VYNE Therapeutics Inc. (VYNE) was downgraded to E+ from D- on 8/19/2024 due to a decline in the growth index, solvency index and total return index. Earnings per share declined from -$0.1502 to -$0.2209, the quick ratio declined from 12.4 to 6.64, and EBIT declined 40.87% from -$7.38M to -$10.4M.
D
Sell
8/15/2024Upgraded
VYNE Therapeutics Inc. (VYNE) was upgraded to D- from E+ on 8/15/2024 due to an increase in the solvency index, volatility index and total return index. The quick ratio increased from 12.37 to 12.4.
VYNE Therapeutics Inc. (VYNE) was upgraded to D- from E+ on 8/15/2024 due to an increase in the solvency index, volatility index and total return index. The quick ratio increased from 12.37 to 12.4.
E
Sell
3/14/2023Downgrade
VYNE Therapeutics Inc. (VYNE) was downgraded to E+ from D- on 03/14/2023.
VYNE Therapeutics Inc. (VYNE) was downgraded to E+ from D- on 03/14/2023.
D
Sell
3/7/2023Downgrade
VYNE Therapeutics Inc. (VYNE) was downgraded to D- from D on 3/7/2023 due to a decline in the volatility index.
VYNE Therapeutics Inc. (VYNE) was downgraded to D- from D on 3/7/2023 due to a decline in the volatility index.
D
Sell
2/17/2023Upgraded
VYNE Therapeutics Inc. (VYNE) was upgraded to D from E+ on 2/17/2023 due to an increase in the volatility index and total return index.
VYNE Therapeutics Inc. (VYNE) was upgraded to D from E+ on 2/17/2023 due to an increase in the volatility index and total return index.
E
Sell
2/8/2023Downgrade
VYNE Therapeutics Inc. (VYNE) was downgraded to E+ from D- on 2/8/2023 due to a decline in the solvency index and valuation index. The quick ratio declined from 7.04 to 5.99.
VYNE Therapeutics Inc. (VYNE) was downgraded to E+ from D- on 2/8/2023 due to a decline in the solvency index and valuation index. The quick ratio declined from 7.04 to 5.99.
D
Sell
11/9/2022Upgraded
VYNE Therapeutics Inc. (VYNE) was upgraded to D- from E+ on 11/9/2022 due to an increase in the volatility index.
VYNE Therapeutics Inc. (VYNE) was upgraded to D- from E+ on 11/9/2022 due to an increase in the volatility index.
E
Sell
10/25/2022Downgrade
VYNE Therapeutics Inc. (VYNE) was downgraded to E+ from D- on 10/25/2022 due to a decline in the volatility index.
VYNE Therapeutics Inc. (VYNE) was downgraded to E+ from D- on 10/25/2022 due to a decline in the volatility index.
D
Sell
10/5/2022Upgraded
VYNE Therapeutics Inc. (VYNE) was upgraded to D- from E+ on 10/5/2022 due to an increase in the volatility index and valuation index.
VYNE Therapeutics Inc. (VYNE) was upgraded to D- from E+ on 10/5/2022 due to an increase in the volatility index and valuation index.
E
Sell
9/20/2022Downgrade
VYNE Therapeutics Inc. (VYNE) was downgraded to E+ from D- on 9/20/2022 due to a decline in the volatility index.
VYNE Therapeutics Inc. (VYNE) was downgraded to E+ from D- on 9/20/2022 due to a decline in the volatility index.
D
Sell
8/30/2022Upgraded
VYNE Therapeutics Inc. (VYNE) was upgraded to D- from E+ on 8/30/2022 due to an increase in the volatility index.
VYNE Therapeutics Inc. (VYNE) was upgraded to D- from E+ on 8/30/2022 due to an increase in the volatility index.
E
Sell
8/15/2022Downgrade
VYNE Therapeutics Inc. (VYNE) was downgraded to E+ from D- on 8/15/2022 due to a noticeable decline in the growth index and volatility index. Earnings per share declined from $0.0843 to -$0.1463, and total revenue declined 29.21% from $178 to $126.
VYNE Therapeutics Inc. (VYNE) was downgraded to E+ from D- on 8/15/2022 due to a noticeable decline in the growth index and volatility index. Earnings per share declined from $0.0843 to -$0.1463, and total revenue declined 29.21% from $178 to $126.
D
Sell
6/16/2022Downgrade
VYNE Therapeutics Inc. (VYNE) was downgraded to D- from D on 6/16/2022 due to a decline in the solvency index, volatility index and growth index. Total revenue declined 92.23% from $2.29M to $178.
VYNE Therapeutics Inc. (VYNE) was downgraded to D- from D on 6/16/2022 due to a decline in the solvency index, volatility index and growth index. Total revenue declined 92.23% from $2.29M to $178.
D
Sell
5/16/2022Upgraded
VYNE Therapeutics Inc. (VYNE) was upgraded to D from E+ on 05/16/2022.
VYNE Therapeutics Inc. (VYNE) was upgraded to D from E+ on 05/16/2022.
E
Sell
5/13/2022Downgrade
VYNE Therapeutics Inc. (VYNE) was downgraded to E+ from D on 5/13/2022 due to a decline in the volatility index.
VYNE Therapeutics Inc. (VYNE) was downgraded to E+ from D on 5/13/2022 due to a decline in the volatility index.
D
Sell
5/4/2022Upgraded
VYNE Therapeutics Inc. (VYNE) was upgraded to D from E+ on 05/04/2022.
VYNE Therapeutics Inc. (VYNE) was upgraded to D from E+ on 05/04/2022.
E
Sell
5/1/2022Downgrade
VYNE Therapeutics Inc. (VYNE) was downgraded to E+ from D on 5/1/2022 due to a decline in the volatility index.
VYNE Therapeutics Inc. (VYNE) was downgraded to E+ from D on 5/1/2022 due to a decline in the volatility index.
D
Sell
4/21/2022Upgraded
VYNE Therapeutics Inc. (VYNE) was upgraded to D from E+ on 04/21/2022.
VYNE Therapeutics Inc. (VYNE) was upgraded to D from E+ on 04/21/2022.
E
Sell
4/20/2022Downgrade
VYNE Therapeutics Inc. (VYNE) was downgraded to E+ from D on 04/20/2022.
VYNE Therapeutics Inc. (VYNE) was downgraded to E+ from D on 04/20/2022.
D
Sell
4/18/2022Upgraded
VYNE Therapeutics Inc. (VYNE) was upgraded to D from D- on 4/18/2022 due to an increase in the volatility index.
VYNE Therapeutics Inc. (VYNE) was upgraded to D from D- on 4/18/2022 due to an increase in the volatility index.
D
Sell
3/22/2022Downgrade
VYNE Therapeutics Inc. (VYNE) was downgraded to D- from D on 3/22/2022 due to a noticeable decline in the growth index, volatility index and total return index. Total revenue declined 43.91% from $4.09M to $2.29M.
VYNE Therapeutics Inc. (VYNE) was downgraded to D- from D on 3/22/2022 due to a noticeable decline in the growth index, volatility index and total return index. Total revenue declined 43.91% from $4.09M to $2.29M.
D
Sell
11/9/2021Upgraded
VYNE Therapeutics Inc. (VYNE) was upgraded to D from E+ on 11/09/2021.
VYNE Therapeutics Inc. (VYNE) was upgraded to D from E+ on 11/09/2021.
E
Sell
11/8/2021Downgrade
VYNE Therapeutics Inc. (VYNE) was downgraded to E+ from D on 11/8/2021 due to a noticeable decline in the total return index and volatility index.
VYNE Therapeutics Inc. (VYNE) was downgraded to E+ from D on 11/8/2021 due to a noticeable decline in the total return index and volatility index.
D
Sell
4/1/2021Upgraded
VYNE Therapeutics Inc. (VYNE) was upgraded to D from D- on 4/1/2021 due to a large increase in the growth index, volatility index and total return index. Total revenue increased 31.11% from $3.27M to $4.29M, EBIT increased 26.4% from -$23.49M to -$17.29M, and earnings per share increased from -$0.5894 to -$0.5489.
VYNE Therapeutics Inc. (VYNE) was upgraded to D from D- on 4/1/2021 due to a large increase in the growth index, volatility index and total return index. Total revenue increased 31.11% from $3.27M to $4.29M, EBIT increased 26.4% from -$23.49M to -$17.29M, and earnings per share increased from -$0.5894 to -$0.5489.
D
Sell
1/22/2021Upgraded
VYNE Therapeutics Inc. (VYNE) was upgraded to D- from E+ on 1/22/2021 due to an increase in the total return index and volatility index.
VYNE Therapeutics Inc. (VYNE) was upgraded to D- from E+ on 1/22/2021 due to an increase in the total return index and volatility index.
E
Sell
1/7/2021Downgrade
VYNE Therapeutics Inc. (VYNE) was downgraded to E+ from D- on 1/7/2021 due to a decline in the volatility index.
VYNE Therapeutics Inc. (VYNE) was downgraded to E+ from D- on 1/7/2021 due to a decline in the volatility index.
D
Sell
12/8/2020Upgraded
VYNE Therapeutics Inc. (VYNE) was upgraded to D- from E+ on 12/8/2020 due to an increase in the total return index and volatility index.
VYNE Therapeutics Inc. (VYNE) was upgraded to D- from E+ on 12/8/2020 due to an increase in the total return index and volatility index.
E
Sell
12/1/2020Upgraded
VYNE Therapeutics Inc. (VYNE) was upgraded to E+ from E on 12/1/2020 due to an increase in the volatility index.
VYNE Therapeutics Inc. (VYNE) was upgraded to E+ from E on 12/1/2020 due to an increase in the volatility index.
E
Sell
9/1/2020Upgraded
Menlo Therapeutics Inc. (MNLO) was upgraded to E from E- on 9/1/2020 due to a noticeable increase in the growth index, solvency index and valuation index. Total revenue increased 567.89% from $1.75M to $11.69M, the quick ratio increased from 1.59 to 4.52, and operating cash flow increased 31.32% from -$52.21M to -$35.86M.
Menlo Therapeutics Inc. (MNLO) was upgraded to E from E- on 9/1/2020 due to a noticeable increase in the growth index, solvency index and valuation index. Total revenue increased 567.89% from $1.75M to $11.69M, the quick ratio increased from 1.59 to 4.52, and operating cash flow increased 31.32% from -$52.21M to -$35.86M.
E
Sell
6/3/2020None
VYNE Therapeutics Inc. (VYNE) was downgraded to E- from U on 06/03/2020.
VYNE Therapeutics Inc. (VYNE) was downgraded to E- from U on 06/03/2020.
NASDAQ
04/11/2025 4:00PM Eastern
Quotes delayed
